Your browser version may not work well with NCBI's Web applications. More information here...
1: J Rheumatol. 2004 Oct;31(10):2071-5.Click here to read Links

Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.

Verbsky JW, White AJ.

Division of Rheumatology, Department of Pediatrics, Washington University School of Medicine, St. Lousis Children's Hospital, Missouri 63110, USA.

Systemic onset juvenile rheumatoid arthritis (SOJRA) is a multisystem disease characterized by high fever, rash, arthritis, serositis, splenomegaly, and laboratory evidence of systemic inflammation. Anticytokine therapies show promise in the treatment of chronic arthritides in children. We describe the use of the recombinant interleukin 1 receptor antagonist anakinra in 2 patients with therapy resistant SOJRA. Both patients experienced immediate and sustained resolution of symptoms and laboratory markers of inflammation, in one case after years of treatment with other immunosuppressive therapies.

PMID: 15468378 [PubMed - indexed for MEDLINE]

Related Articles

Patient Drug Information
  • Anakinra (Kineret®) Anakinra is used, alone or in combination with other medications, to reduce the pain and swelling associated with rheumatoid arthritis. Anakinra is in a class of medications called interleukin antagonists. It works by bl...
    » read more ...